SAB BIOTHERAPEUTICS, INC. Operating Income
SAB BIOTHERAPEUTICS, INC. (SABS) reported Operating Income of -$23.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-06-30 was -$23.38M.
- SAB BIOTHERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-03-31 was -$20.00M.
- SAB BIOTHERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-12-31 was -$15.77M.
- SAB BIOTHERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-09-30 was -$12.68M.
- SAB BIOTHERAPEUTICS, INC. operating income (loss) for fiscal 2025 was -$48.95M.
- SAB BIOTHERAPEUTICS, INC. operating income (loss) for fiscal 2024 was -$42.91M.
- SAB BIOTHERAPEUTICS, INC. operating income (loss) for fiscal 2023 was -$38.08M.
- SAB BIOTHERAPEUTICS, INC. operating income (loss) for fiscal 2022 was -$28.92M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$23.38M 10-Q · filed 2026-08-06 | -$43.38M 10-Q · filed 2026-08-06 | -$59.14M derived: sum of 3 quarters · filed 2026-08-06 | -$71.82M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | -$20.00M 10-Q · filed 2026-05-12 | -$35.77M derived: sum of 2 quarters · filed 2026-05-12 | -$48.45M derived: sum of 3 quarters · filed 2026-05-12 | -$58.18M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | -$15.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$28.45M derived: sum of 2 quarters · filed 2026-03-09 | -$38.18M derived: sum of 3 quarters · filed 2026-08-06 | -$48.95M 10-K · filed 2026-03-09 | |||
| 2025-09-30 | -$12.68M 10-Q · filed 2025-11-14 | -$22.41M derived: sum of 2 quarters · filed 2026-08-06 | -$33.18M 10-Q · filed 2025-11-14 | -$43.19M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | -$9.73M 10-Q · filed 2026-08-06 | -$9.73M 10-Q · filed 2025-08-07 | -$20.50M 10-Q · filed 2026-08-06 | -$20.50M 10-Q · filed 2025-08-07 | -$30.51M derived: sum of 3 quarters · filed 2026-08-06 | -$41.82M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$10.77M 10-Q · filed 2026-05-12 | -$20.78M derived: sum of 2 quarters · filed 2026-05-12 | -$32.09M derived: sum of 3 quarters · filed 2026-05-12 | -$42.29M derived: sum of 4 quarters · filed 2026-05-12 | |||
| 2024-12-31 | -$10.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$21.32M derived: sum of 2 quarters · filed 2026-03-09 | -$31.52M derived: sum of 3 quarters · filed 2026-03-09 | -$42.91M 10-K · filed 2026-03-09 | |||
| 2024-09-30 | -$11.31M 10-Q · filed 2025-11-14 | -$21.51M derived: sum of 2 quarters · filed 2025-11-14 | -$32.90M 10-Q · filed 2025-11-14 | -$51.78M derived: sum of 4 quarters · filed 2025-11-14 | |||
| 2024-06-30 | -$10.20M 10-Q · filed 2025-08-07 | -$21.59M 10-Q · filed 2025-08-07 | -$40.47M derived: sum of 3 quarters · filed 2025-08-07 | -$45.79M derived: sum of 4 quarters · filed 2025-08-07 | |||
| 2024-03-31 | -$11.39M 10-Q · filed 2025-05-09 | -$30.26M derived: sum of 2 quarters · filed 2025-05-09 | -$35.59M derived: sum of 3 quarters · filed 2025-05-09 | -$42.06M derived: sum of 4 quarters · filed 2025-05-09 | |||
| 2023-12-31 | -$18.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$24.20M derived: sum of 2 quarters · filed 2025-03-31 | -$30.67M derived: sum of 3 quarters · filed 2025-03-31 | -$38.08M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | -$5.32M 10-Q · filed 2024-11-06 | -$11.80M derived: sum of 2 quarters · filed 2024-11-06 | -$19.20M 10-Q · filed 2024-11-06 | -$27.06M derived: sum of 4 quarters · filed 2024-11-06 | |||
| 2023-06-30 | -$6.48M 10-Q · filed 2024-08-08 | -$13.88M 10-Q · filed 2024-08-08 | -$21.74M derived: sum of 3 quarters · filed 2024-08-08 | -$29.55M derived: sum of 4 quarters · filed 2024-08-08 | |||
| 2023-03-31 | -$7.40M 10-Q · filed 2024-05-20 | -$15.26M derived: sum of 2 quarters · filed 2024-05-20 | -$23.07M derived: sum of 3 quarters · filed 2024-05-20 | -$29.61M derived: sum of 4 quarters · filed 2024-05-20 | |||
| 2022-12-31 | -$7.86M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$15.67M derived: sum of 2 quarters · filed 2024-03-29 | -$22.21M derived: sum of 3 quarters · filed 2024-03-29 | -$28.92M 10-K · filed 2024-03-29 | |||
| 2022-09-30 | -$7.81M 10-Q · filed 2023-11-13 | -$14.35M derived: sum of 2 quarters · filed 2023-11-13 | -$21.06M 10-Q · filed 2023-11-13 | -$28.40M derived: sum of 4 quarters · filed 2023-11-13 | |||
| 2022-06-30 | -$6.54M 10-Q · filed 2023-08-21 | -$13.25M 10-Q · filed 2023-08-21 | -$20.59M derived: sum of 3 quarters · filed 2023-08-21 | -$24.58M derived: sum of 4 quarters · filed 2023-08-21 | |||
| 2022-03-31 | -$6.71M 10-Q · filed 2023-05-15 | -$14.05M derived: sum of 2 quarters · filed 2023-05-15 | -$18.04M derived: sum of 3 quarters · filed 2023-05-15 | -$20.91M derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | -$7.34M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-04-28 | -$11.33M derived: sum of 2 quarters · filed 2023-04-28 | -$14.21M derived: sum of 3 quarters · filed 2023-04-28 | -$13.39M 10-K/A · filed 2023-04-28 | |||
| 2021-09-30 | -$3.99M 10-Q · filed 2022-11-14 | -$335.55K 10-Q · filed 2021-11-22 | -$6.86M derived: sum of 2 quarters · filed 2022-11-14 | -$6.05M 10-Q · filed 2022-11-14 | -$704.01K 10-Q · filed 2021-11-22 | ||
| 2021-06-30 | -$2.87M 10-Q · filed 2022-08-10 | -$256.85K 10-Q · filed 2021-08-09 | -$2.06M 10-Q · filed 2022-08-10 | -$368.46K 10-Q · filed 2021-08-09 | |||
| 2021-03-31 | $813.92K 10-Q · filed 2022-05-12 | -$111.61K 10-Q · filed 2021-05-21 | |||||
| 2020-12-31 | $20.56M 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |